Press Release: Aqualung Therapeutics : Aqualung Therapeutics Receives the AZ-Bio Fast Lane Award and Achieves Key FDA-Related Milestones

TUCSON, AZ / ACCESSWIRE / September 13th, 2022 / Aqualung Therapeutics, an immunotherapeutics biotech company with an anti-inflammatory therapeutic platform for serious unchecked inflammatory disorders, announced the achievement of two key FDA milestones for their therapeutic mAb ALT-100. First is the successful FDA IND submission for the indication of Acute Respiratory Distress Syndrome (ARDS). Second is the scheduling of an FDA Pre-IND type B